Biotest AG / Final Results 22.02.2008 Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Biotest marked increase in sales and earnings recorded in 2007 Dreieich, 22 February 2008. The Biotest Group recorded sales totalling EUR 326.4 million in financial year 2007, according to preliminary figures, which is 15.8% up on the figure for the previous year (EUR 281.9 million). Earnings before interest and tax (EBIT) rose by 22.6% to EUR 38.5 million (2006: EUR 31.4 million). The EBIT reflects charges amounting to EUR 1.5 million resulting from the acquisition of Nabi Biopharmaceuticals Inc. plasma proteins business which was completed in December 2007. The charges relate to the higher write-downs associated with the purchase price allocation. The sales recorded by the plasma proteins business in the US since the acquisition have not been posted in the accounts. In the Pharmaceutical segment, Biotest sales totalled EUR 247.0 million, representing a 20.5% increase on 2006, while in the Diagnostic segment, Biotest was able to increase its sales by 3.3% to EUR 79.4 million, growth attributable to the sustained success of the microbiology business. Biotest will be announcing the final figures for financial year 2007 on 20 March 2008. For the year ahead, Biotest is forecasting sales of an order of magnitude totalling EUR 400 million, with a 10% increase in EBIT compared to the previous year. Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest AG, Dreieich, Germany, is a company that researches and manufactures pharmaceutical, biotherapeutic and diagnostic products and has specialised in immunology and haematology. In its Pharmaceutical segment, Biotest develops immunoglobulins, clotting factors and albumins based on human blood plasma. These are used for diseases of the immune system or haematopoietic system. In the Biotherapeutic segment, Biotest researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and blood cancer. The Diagnostic segment spans reagents and immunological diagnostics which are used, for example, in blood transfusions and transplants. Biotest has around 1,800 employees worldwide and its shares are listed in the Frankfurt Stock Exchange's Prime Standard. Biotest AG: Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de Dr. Michael Ramroth Tel: +49 (0)6103 801-338 Fax: +49 (0)6103 801-347 e-mail: michael_ramroth@biotest.de WKN, ISIN ordinary share: 522720, DE0005227201 WKN, ISIN preference share: 522723, DE0005227235 Listed: Prime Standard/official trading Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart DGAP 22.02.2008 --------------------------------------------------------------------------- Language: English Issuer: Biotest AG Landsteinerstr. 5 63303 Dreieich Deutschland Phone: +49 - 6103 / 801 - 0 Fax: +49 - 6103 / 801 - 150 E-mail: mail@biotest.de Internet: www.biotest.de ISIN: DE0005227201, DE0005227235 WKN: 522720, 522723 Indices: SDAX Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Biotest AG: Biotest marked increase in sales and earnings recorded in 2007
| Source: EQS Group AG